There is a huge demand for innovative drugs  to treat human diseases in China and the world. In  2019, China’s domestic drug sales reached  RMB1.8 trillion. With SciTech Pharma’s proven  system and core competencies in place, we carry  out our innovative drug design program to develop  high-quality Small Molecule Drugs targeting  Solid Tumors, Autoimmune Diseases and CNS  Diseases such as Parkinson’s Disease and ALS.

SciTech Pharma’s ultimate mission is to provide solutions to the challenges of drug discovery using our innovative Drug Design Program. We are committed to being an innovative research-intensive, bio-pharmaceutical company using powerful Artificial Intelligence and Deep Learning tools to expand the frontier of knowledge in drug discoveries.

With strong financial support from our majority shareholder and connections in the international biotech industry, SciTech Pharma has built a world-class scientific team with decades of experience in various fields relevant to our future development.

Since the company’s inception in 2015, SciTech Pharma has reached many research milestones including clinical trials in Oncology drugs that promise to have very significant market potential. We expect to enroll many more compounds in preclinical and clinical trials in 2023 and beyond. With a robust pipeline and powerful research tools, SciTech Pharma is looking forward to further expanding and welcoming additional experts to our growing scientific team.

                                                                 Qiang ZHANG, Ph.D.

                                                           Chief Executive Officer and Chief Scientific Officer